AstraZeneca Plc has entered into a licensing and collaboration agreement with two leading Belgian research institutes to explore the potential of inhibiting the MALT1 protein in the treatment of auto-immune disorders and certain cancers. ---Subscribe to MedNous to access this article--- Company News Research & University News
